Efficacy and Safety of a Tri-Valent Ready-to-Use Porcine Circovirus Type 2a, and Vaccine in Weaned Pigs.

: This study describes multiple trials demonstrating the safety and efficacy of a tri-valent vaccine against diseases caused by Porcine Circovirus Types 2a and 2d (PCV2a, PCV2d), , and . : For each of the PCV2a and PCV2d onset of immunity (OOIs) and duration of immunity (DOI) studies, 25 pigs were vaccinated with a tri-valent vaccine and 25 with placebo. After dual challenge with PCV2a and porcine reproductive and respiratory virus (PRRSV) (OOI) or single challenge with PCV2d (OOI and DOI), respectively, viremia and lymphoid depletion data were collected.

Quadrivalent neuraminidase RNA particle vaccine protects pigs against homologous and heterologous strains of swine influenza virus infection.

Influenza A virus in swine (IAV-S) continues to cause significant negative impact to both sows and growing pigs. The viral hemagglutinin (HA) and neuraminidase (NA) genes continue to evolve with HA diversifying at a faster rate than NA. Depending on country, whole inactivated virus (WIV) commercial and autogenous vaccines, as well as veterinary prescription vaccines targeting HA, are currently available.